Guardant Health Grabs $50M Series C for Cancer Test
February 04, 2015
Guardant Health has secured $50 million in Series C funding, bringing its VC total raised to near $100 million. Lightspeed Venture Partners led the round, with new investor Formation 8 and existing investors Khosla Ventures and Sequoia Capital also participating. Proceeds will be used in part to expand the availability of Guardant360, the company's cancer blood test platform that helps identify critical tumor genomic alterations in real time. Guardant's $9 million Series A in February 2014 generated a valuation of $40 million; in April, its next funding generated a $167 million valuation.